Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- Status
- WITHDRAWN
- Phase
- PHASE3
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
- Status
- TERMINATED
- Phase
- PHASE1
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
- Status
- TERMINATED
- Phase
- PHASE2
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Imexon for Relapsed Follicular and Aggressive Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- N/A